Solution Group Berhad to Start Local Fill and Finish of CanSinoBIO’s COVID-19 Vaccine in Malaysia
CanSino Biologics Inc. and Solution Biologics Sdn Bhd (“SOLBIO”), a wholly owned subsidiary of Solution Group Berhad, jointly announced that the first shipment of the active pharmaceutical ingredients (“APIs”) of CanSinoBIO’s Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (“Ad5-nCoV”, trade name: Convidecia®) in bulk form has arrived in Malaysia.
The companies are ready to conduct the first local Fill and Finish at the facility located at the Technology Park Malaysia and distribute the single-dose Convidecia® to the region, representing another milestone that adds to CanSinoBIO’s expanded presence in ASEAN.
SOLBIO is the local manufacturing partner of CanSinoBIO to develop, manufacture, and commercialize CanSinoBIO’s COVID-19 vaccine in the ASEAN market. SOLBIO received the Good Manufacturing Practices (“GMP”) certification from the National Pharmaceutical Regulatory Agency (“NPRA”) of Malaysia in February 2022, which enabled CanSinoBIO to build up fast and scalable local production of its COVID-19 vaccine and have better control over shelf life to optimize vaccine roll-out following an earlier cooperation agreement between the two parties.
The finished vaccine products in vials can be easily stored and transported in refrigerated facilities between 2°C to 8°C and distributed to Malaysia and other ASEAN countries. Malaysia is expected to serve as a regional vaccine manufacturing hub for CanSinoBIO, with its annual production reaching 36 million vials at full capacity.
CanSinoBIO has been an active player in supporting the COVID-19 vaccination drive in Malaysia and globally. Malaysia and Indonesia became the first ASEAN countries to approve CanSinoBIO’s Convidecia® as a heterologous booster in March 2022. Malaysia is the first overseas country that granted approval to CanSinoBIO to conduct clinical trials of its inhaled COVID-19 vaccine, Convidecia Ai®. Convidecia Air® is currently included in national-wide heterologous booster programs in China and Morocco.
About Cansino Biologics
CanSino Biologics Inc (CanSino Biologics) is a biopharmaceutical company that develops, manufactures and commercializes pneumococcal, polyvalent conjugate and adenovirus-based recombinant TB vaccines. The company is investigating Ad5-EBOV, an adenovirus type 5 vector, to treat Ebola virus; MCV2 and MCV4 vaccines for the prevention of Neisseria meningitidis bacteria. It is also evaluating DTcP vaccine against pertussis caused after primary vaccination in infants and children; and PBPV, PCV13i vaccines, targeting pneumococcal diseases. CanSino Biologics utilizes Adenovirus-based viral vector vaccine, conjugation, formulation, and protein structure design and recombinant technology to develop vaccines. It works in partnership with MC Master University, National Research Council of Canada and Beijing Institute of Biotechnology. CanSino Biologics is headquartered in Tianjin, China.